Head-to-head evidence
SP2086 vs Vildagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
SP2086
Developed by Jiangsu Hengrui Pharmaceuticals
NCT01970033 · Phase 3 · status unknown
This is a large, randomized, quadruple-blind, placebo-controlled trial using the standard glycemic control measure for diabetes as its primary endpoint, but no results have been posted yet, so whether the drug lowered HbA1c more than placebo is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Vildagliptin · Galvus
Developed by Novartis
NCT00099866 · Phase 3 · completed
The study was randomized and double-blind, with an active metformin comparator and 570 participants. Its primary endpoint was the surrogate measure of HbA1c change, and because no trial results are posted, it cannot be determined whether the primary comparison was favorable.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SP2086's landscape · Vildagliptin's landscape